You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 18, 2024

Claims for Patent: 6,284,770

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 6,284,770

Title:	Medicaments for the treatment of non-constipated female irritable bowel syndrome
Abstract:	This invention relates to the use of 5-HT3 receptor antagonists in the treatment of nonconstipated female IBS patients.
Inventor(s):	Mangel; Allen Wayne (Chapel Hill, NC), Northcutt; Allison Ruth (Raleigh, NC)
Assignee:	Glaxo Wellcome Inc. (Research Triangle Park, NC)
Application Number:	09/529,050
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,284,770
Patent Claims:	1. A method of treatment of nonconstipated female IBS which comprises administering an effective amount of a 5-HT.sub.3 receptor antagonist or a pharmaceutically acceptable derivative thereof selected from the group consisting of granisetron, azasetron, tropisetron, ramosetron, ondansetron, lerisetron, (R) zacopride, cilansetron, itasetron, indisetron and dolasetron and pharmaceutically acceptable derivatives thereof. 2. A method of treatment of nonconstipated female IBS which comprises administering an effective amount of alosetron or a pharmaceutically acceptable derivative. 3. A method of treatment according to claim 2 wherein alosetron is in the form of its hydrochloride. 4. A method of treatment of diarrhea-predominant female IBS which comprises administering an effective amount of a 5-HT.sub.3 receptor antagonist or a pharmaceutically acceptable derivative thereof selected from the group consisting of granisetron, azasetron, tropisetron, ramosetron, ondansetron, lerisetron, (R) zacopride, cilansetron, itasetron, indisetron and dolasetron and pharmaceutically acceptable derivatives thereof. 5. A method of treatment of diarrhea-predominant female IBS which comprises administering an effective amount of alosetron or a pharmaceutically acceptable derivative thereof. 6. A method of treatment according to claim 5, wherein alosetron is in the form of its hydrochloride. 7. A method of treatment of alternating constipation/diarrhea IBS which comprises administering an effective amount of a 5-HT.sub.3 receptor antagonist or a pharmaceutically acceptable derivative thereof selected from the group consisting of granisetron, azasetron, tropisetron, ramosetron, ondansetron, lerisetron, (R) zacopride, cilansetron, itasetron, indisetron and dolasetron and pharmaceutically acceptable derivatives thereof. 8. A method of treatment of alternating constipation/diarrhea IBS which comprises administering an effective amount of alosetron or a pharmaceutically acceptable derivative thereof. 9. A method of treatment according to claim 8, wherein alosetron is in the form of its hydrochloride.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.